ARDS
Aridis Pharmaceuticals, Inc.
Set alert
- YTD
- -86.67%
- 1 year
- -86.21%
- Open
- 0.00145
- Prev close
- 0.0002
- Mkt cap
- 8.91K
- Vol
- 10
- Avg vol
- 4.74K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.00145
- High
- 0.00145
- Forward P/E
- 1.35
- Beta
- 0.78
- Short ratio
- 0.22
- Inst. own
- 11.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 0.2338
- 200-d avg
- 0.63715
- 1y target
- 10.00
News
5 days ago gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced he
1 month ago gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
1 month ago gurufocus.com
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
5 months ago gurufocus.com
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
5 months ago gurufocus.com
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR
7 months ago globenewswire.com
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart…
1 year ago globenewswire.com
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced…
1 year ago globenewswire.com
Aridis Provides Corporate Update
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent…
2 years ago globenewswire.com
Aridis Provides Corporate Update
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent…
2 years ago globenewswire.com
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today…
2 years ago globenewswire.com
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of…
2 years ago globenewswire.com
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective…
2 years ago globenewswire.com
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health
3 years ago globenewswire.com
Aridis Pharmaceuticals Announces $2 Million Offering
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
3 years ago benzinga.com
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
3 years ago benzinga.com
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
3 years ago globenewswire.com
Aridis Receives Agreement from the European Medicines Agency (EMA) on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed…
3 years ago zacks.com
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
3 years ago globenewswire.com
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective…
3 years ago zacks.com
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
3 years ago zacks.com
Aridis (ARDS) Up After FDA Nod for Pneumonia Drug Study Design
Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.
3 years ago pennystocks.com
Utilizing Fundamental Analysis for Your Penny Stocks? 3 Tips
Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer…
-
3 years ago benzinga.com
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P…
-
3 years ago benzinga.com
Why Capri Holdings Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares jumped 143% to $0.45 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 76 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 93 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
-
3 years ago benzinga.com
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 79 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Dow Surges Over 100 Points; World Acceptance Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 100 points on Thursday. The Dow traded up 0.35% to 33,863.38 while the NASDAQ rose 1.33% to 11,463.77. The S&P 500…
-
3 years ago benzinga.com
US GDP Rises 2.9% In Q4; Crude Oil Up Over 1%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.27% to 33,834.44 while the…
-
3 years ago benzinga.com
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products.
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
4 years ago benzinga.com
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Gainers
-
4 years ago benzinga.com
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of…
-
4 years ago benzinga.com
Why MSP Recovery Is Trading Higher By Over 21%, Here Are 61 Stocks Moving In Monday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares surged 78% to $2.2399 as the stock continued to see momentum despite the company last week announcing it is not aware of any developments…
-
4 years ago benzinga.com
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
Gainers Getty Images Holdings, Inc. (NYSE: GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal…
-
4 years ago benzinga.com
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
63 Biggest Movers From Yesterday
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
-
4 years ago benzinga.com
44 Stocks Moving In Thursday's Mid-Day Session
Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David Hollander, MD, MBA, to its Board of Directors.
-
4 years ago benzinga.com
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning session, 216 companies made new 52-week lows.
-
5 years ago benzinga.com
64 Biggest Movers From Yesterday
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares climbed 128.8% to settle at $9.06 on Tuesday.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday